Introduction {#s1}
============

Major depressive disorder (MDD) is a major economic and social burden owing to its high prevalence rate and disabling symptoms ([@CIT0019]). Although the newer antidepressant drugs are generally well tolerated and relatively effective, less than one-half of patients achieve remission with the first prescribed antidepressant ([@CIT0028]). Partial remission results in continued suffering and higher costs ([@CIT0034]).

There have been many attempts to identify variables that could predict antidepressant response, with a variety of predictors proposed that include clinical, psychosocial, psychophysiological, neuropsychological, neuroimaging, and genetic factors ([@CIT0005]; [@CIT0024]). While genetic polymorphisms may contribute 50% or more to antidepressant response, a more effective strategy should consider interactions between the various genetic factors (gene × gene) as well as their interaction with clinical and other environmental modulators (gene × environment) ([@CIT0012]). In the main, genetic research focuses on genetic polymorphisms of target proteins that relate to mechanisms of antidepressant drug action ([@CIT0031]). As the monoaminergic theory remains the theoretical basis for the effect of most current antidepressant drugs, a number of genes coding for metabolic enzymes, transporters, and receptors in monoamine systems have been studied and reported to affect antidepressant drug response (reviewed by [@CIT0030]; [@CIT0012]). As the serotonin transporter and the 5-HT1A receptor are strongly implicated in antidepressant action, their genetic variability has been well studied in this respect ([@CIT0016]). Investigations into an insertion--deletion (L/S)polymorphism(5-HTTLPR)associated with antidepressant response found that L-allele carriers have a faster and better response to antidepressants, if they are Caucasians, but allele frequencies and results of pharmacogenetic studies vary between different ethnic groups ([@CIT0017]). Other genes involved in serotonin and noradrenaline neurotransmission, including 5-HT6, 5-HT1A and 5-HT2A receptors, monoamine oxidase A, the noradrenaline transporter SLC6A2, and tryptophan hydroxylases (TPH1 and 2) among others also provide good candidates for pharmacogenetic study ([@CIT0030]; [@CIT0020]; [@CIT0023]). The single nucleotide polymorphism (SNP) rs6295 of 5-HT1A receptor has been widely studied, because the G allele was associated with an upregulation of the receptor ([@CIT0001]). TPH2 is the rate-limiting biosynthetic enzyme for serotonin that is preferentially expressed in the brain and has been implicated in the pathogenesis and treatment of major depressive disorder ([@CIT0041]; [@CIT0035]). Several SNPs in this gene have been associated with affective disorders and their treatment response. [@CIT0008] found that the minor alleles of SNPs rs11178997 (T-473A) and rs11178998 (A90G) in the 5' region were significantly overrepresented in bipolar affective disorder patients when compared with controls. In a recent meta-analyses, it was found that rs4760820 and rs11178998 demonstrated a strong genetic association with bipolar disorder ([@CIT0015]). The promoter polymorphism rs4570625 (T-703G) of TPH2 has been found associated with paranoid schizophrenia in Han Chinese ([@CIT0039]).[@CIT0035] reported that the proportion of intron 5 SNP rs2171363 heterozygotes had an increased chance of responding to an 8-week antidepressant treatment as compared with rs2171363 homozygotes (CC or TT).

Identifying environmental factors that may interact with different genetic pathways in determining antidepressant efficacy would be a valuable step towards personalized medicine in the treatment of depression. Environmental factors such as childhood maltreatment and stressful life events certainly show independent effects on antidepressant response ([@CIT0027]), and there are several reports of significant interactions with genetic polymorphisms in these effects ([@CIT0037]). Thus, [@CIT0025] reported that stressors modulate the effects of a common functional polymorphism (5-HTTLPR) of the serotonin transporter gene (SLC6A4) on outcome of pharmacological treatment of depression. It was also found that variants in BDNF and ST8SIA may delay the early response to antidepressants in subjects not exposed to stressors at the illness onset, with a remarkable gene-environment interaction ([@CIT0026]). [@CIT0018] also reported variation in the 5-HTTLPR and STin4 polymorphisms of SLC6A4 interacted with stressful life events to modify antidepressant effects. Our own studies identified that the *HTR1B* SNP rs6298 demonstrated interaction with recent stress in its association with antidepressant response, while rs7305115 of *TPH2* and rs5569 of the noradrenaline transporter gene *SLC6A2* interacted with childhood trauma to influence response to antidepressants ([@CIT0040], [@CIT0041]).

Our previous studies focused on polymorphisms within exonic sequences of candidate genes involved primarily with serotonin and noradrenaline neurotransmission. In the current work, we extended this study, again using a candidate gene approach, but including intronic and promoter polymorphisms. At the same time, we aimed to replicate some significant results reported in Caucasians in our Chinese Han sample. Again, interactions between these polymorphisms and stressful life events were analyzed to obtain a better understanding of the role of both genetic and clinical factors in the response to antidepressant treatment.

METHODS {#s2}
=======

Subjects {#s3}
--------

The subjects were Chinese Han in- and out-patients referred to 5 hospitals in Beijing, Nanjing, Changsha, Yangzhou, and Huai'an. All recruited patients were 18 to 60 years old, had a baseline HDRS-17 score of \>17, presented depressive symptoms for at least 2 weeks, and met DSM-IV for nonpsychotic MDD. All subjects were newly diagnosed or recently relapsed patients drug-free for over 2 weeks. The patients were diagnosed by 2 independent senior psychiatrists and confirmed by a third psychiatrist who was blind to the previous evaluations. Exclusion criteria included documented history of diagnoses on Axis 1 (including substance misuse, schizophrenia, schizoaffective disorder, bipolar disorder, generalized anxiety disorder, panic disorder, or obsessive compulsive disorder) of DSM-IV, personality disorder, mental retardation, pregnancy, lactation, primary organic disease and other medical illnesses impairing psychiatric evaluation, or a history of electroconvulsive therapy within the previous 6 months. Patients who suffered a manic episode during the 12 months after admission were excluded retrospectively. All patients were interviewed and diagnosed by 2 independent senior psychiatrists, and the diagnosis was confirmed by a third psychiatrist blinded to the previous evaluations. All subjects provided separate written informed consent for study participation, which was approved by each hospital ethical committee in accordance with the Declaration of Helsinki.

Antidepressant Treatment and Clinical Evaluation {#s4}
------------------------------------------------

MDD patients entering the study were given a single antidepressant drug (selective serotonin reuptake inhibitor \[SSRI\] or serotonin norepinephrine reuptake inhibitor \[SNRI\]) according to local clinical practice for at least 6 weeks. Subjects were divided into subgroups by drug type and sex for further analysis. A meeting was held for investigators from the different sites before the onset of the study for assessment, training, and standardization of techniques. The assessing psychiatrists in different clinical centers achieved high inter-rater reliability, with an interclass correlation of at least 0.9. We interviewed each patient every 2 weeks using a standardized protocol across centers, recording treatment duration, dosage, outcome, compliance, and side effects. Severity of depressive symptoms was assessed using HDRS-17 by a trained senior psychiatrist who was blind to patients' genotypes. Adjustment of antidepressant dose and usage of concomitant anxiolytics have been described previously ([@CIT0040]). The primary outcome was "response," defined by a reduction of ≥50% of the baseline HDRS-17 score after 6-week treatments ([@CIT0040]). Patients who changed antidepressant drug or demonstrated nonadherence were retrospectively excluded from the study.

Two evaluation tools, the Childhood Trauma Questionnaire (28-item Short form, CTQ-SF) ([@CIT0003]) and the Life Events Scale (LES) ([@CIT0042]), were used to evaluate the occurrence of stressful life events that took place before the age of 16 years or during the previous year, respectively. Both of them are retrospective self-report questionnaires, and the details have been described previously ([@CIT0040]). Control samples were not included in the present study; therefore, the control values of [@CIT0014] and [@CIT0032] were used to define normal CTQ-SF and LES values, respectively. The total CTQ-SF and NLES scores were dichotomized for use in the gene-environment interaction analyses. A total CTQ score ≥1 SD above the mean CTQ score (35.86 \[8.25\]) of control subjects (≥44.11) was designated "C high adversity"; \<44.11 CTQ scores were designated "C low adversity" ([@CIT0014]). An NLES score ≥1 SD greater than the mean NLES (13.09 \[25.16\]) of control subjects (≥38.25) was designated "N high adversity"; \<38.25 NLES scores were designated "N low adversity" ([@CIT0032]; [@CIT0011]).

Gene Selection and Genotyping Method {#s5}
------------------------------------

The 20 candidate genes tested were selected based on evidence for the involvement of the monoaminergic system in antidepressant mechanisms, and 64 SNPs in these genes were included on the basis of prior genetic or pharmacogenetic study. These were identified using dbSNP (Map to Genome Build: 36.3) and HapMap (Public Release \#24), were screened using the tagging SNP method (<http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap24_B36/>), and then polymorphisms with reported minor allele frequency (MAF) values of ≥5% were prioritized. Most of the SNPs were located in gene exon, intron, or promoter regions. Genomic DNA samples were genotyped using Illumina Golden Gate assays (Illumina Inc). SNPs that were genotyped successfully in \<90% of all samples or had an experimental MAF of \<5% were excluded. Likewise, participants in whom \<90% of the selected markers were successfully determined were also excluded from further analysis.

Statistical Analysis {#s6}
--------------------

Differences in clinical variables between responder and nonresponder groups were evaluated by Pearson's χ^2^ test or ANOVA using SPSS version 13.0 (SPSS Inc). Haploview 4.0 was used to estimate Hardy-Weinberg equilibrium, MAF, linkage disequilibrium (both D' and r^2^), and the percentage of nonmissing each marker (%Gene). Genetic polymorphisms were correlated with therapeutic effects by comparing allele, genotype, and haplotype distributions between responders and nonresponders using UNPHASED-3.0.13 ([@CIT0010]). One thousand random permutations were performed with UNPHASED 3.0.13 software to correct *P* values for multiple testing in the allelic, genotypic, and haplotype association analyses. Furthermore, G×E interactions in association with therapeutic outcome were assessed by logistic regression analysis, using age, HDRS-17 baseline score, sex, and drug type as covariates. Logistic regression analyses were used to assess the effects of CTQ-SF, NLES, genotype, and interactions between genotype and CTQ-SF or NLES on the categorical outcome of antidepressant response. For the G×E analysis, only those SNPs that provided significant findings in the initial association were included (as each SNP thus had a valid a priori hypothesis). Each SNP was tested against 2 environmental conditions. Benjamini and Hochberg Discovery Rate Multiple Testing Correction was applied to the statistical significance of *P* \< .05 ([@CIT0004]).

RESULTS {#s7}
=======

A total of 281 patients met the study entry criteria and completed 6 weeks of antidepressant treatment. Among those, 205 patients achieved response as defined by a 50% improvement in HAMD-17 score. Subgroups were SSRI (n=164) vs SNRI (n=117) and male (n=116) vs female (n=165). Of the 64 SNPs originally tested, 10 SNPs with MAF \<5% or %Gene \<95% were excluded, and 7 further SNPs were not in HW disequilibrium (*P*\<.001), leaving 47 SNPs for inclusion in the analysis ([Table 1](#T1){ref-type="table"}).

###### 

Characteristics of Genotype Markers

  Number   Gene       Name         %geno   HW *P*   MAF     Alleles
  -------- ---------- ------------ ------- -------- ------- ---------
  1        *ADRA2A*   rs12246561   100     1        0.06    A:C
  2        *ADRA2A*   rs521674     100     .2271    0.297   T:A
  3        *ADRB1*    rs17875446   99.6    .0792    0.146   G:T
  4        *COMT*     rs2020917    99.6    .024     0.243   G:A
  5        *COMT*     rs4680       98.2    1        0.277   G:A
  6        *COMT*     rs165774     100     .1613    0.171   G:A
  7        *COMT*     rs165599     99.6    .4011    0.479   A:G
  8        *HTR1A*    rs6295       100     .6515    0.254   C:G
  9        *HTR1B*    rs4140535    99.6    1        0.35    A:G
  10       *HTR1D*    rs674386     100     .6239    0.292   G:A
  11       *HTR2A*    rs7997012    99.6    1        0.234   G:A
  12       *HTR2A*    rs1923884    100     .1605    0.498   G:A
  13       *HTR2A*    rs2224721    99.6    .5167    0.323   C:A
  14       *HTR2A*    rs9316233    100     .2275    0.283   G:C
  15       *HTR2A*    rs2770296    98.6    .7639    0.253   A:G
  16       *HTR2A*    rs1928040    99.6    .804     0.266   A:G
  17       *HTR2A*    rs927544     100     .3008    0.286   A:G
  18       *HTR2A*    rs6313       99.6    .402     0.411   A:G
  19       *HTR2A*    rs6311       99.6    .6041    0.198   G:A
  20       *HTR2C*    rs3795182    99.6             0.157   A:G
  21       *HTR2C*    rs521018     100              0.173   A:C
  22       *HTR3A*    rs1062613    99.3    .9186    0.1     G:A
  23       *HTR3E*    rs10937162   98.9    .7334    0.317   G:C
  24       *HTR3E*    rs6443950    100     .7589    0.173   A:T
  25       *HTR4*     rs1432919    100     .164     0.288   G:A
  26       *HTR4*     rs2278392    100     .2402    0.29    G:A
  27       *HTR5A*    rs1881691    99.6    .3585    0.329   A:C
  28       *HTR5A*    rs3734966    99.3    .5743    0.113   A:G
  29       *HTR5A*    rs1800883    100     .0707    0.463   G:C
  30       *HTR7*     rs1891311    100     .1058    0.183   A:G
  31       *MAOA*     rs979606     99.6             0.407   G:A
  32       *MAOA*     rs2064070    99.6             0.402   A:T
  33       *TH*       rs10770140   98.2    .0153    0.085   A:G
  34       *TH*       rs10840490   100     .0268    0.133   C:G
  35       *TH*       rs7115640    100     .7755    0.069   G:A
  36       *TPH1*     rs7933505    100     .8807    0.496   G:A
  37       *TPH1*     rs1799913    100     .8787    0.493   C:A
  38       *TPH1*     rs1800532    100     1        0.489   C:A
  39       *TPH2*     rs7963717    100     .4763    0.16    A:C
  40       *TPH2*     rs4570625    100     1        0.44    A:C
  41       *TPH2*     rs11178998   100     .396     0.164   A:G
  42       *TPH2*     rs7954758    100     .2892    0.157   A:G
  43       *TPH2*     rs1386494    100     1        0.084   G:A
  44       *TPH2*     rs2171363    100     .269     0.459   A:G
  45       *TPH2*     rs1487278    99.6    .2022    0.305   A:G
  46       *TPH2*     rs1386483    99.6    .579     0.443   A:G
  47       *TPH2*     rs1487279    99.6    .3369    0.454   T:A

Abbreviations: HW *P*, Hardy-Weinberg equilibrium *P*-value; %geno, percentage nonmissing; MAF, minor allele frequency.

Alleles means the major and minor alleles.

The demographic and clinical characteristic of patients in the responder and nonresponder patient groups are shown in [Table 2](#T2){ref-type="table"}. There were no significant differences between the 2 subgroups in gender, age, years of education, or family history of mood disorder. However, the baseline HDRS-17 score was significantly different between the 2 groups (F=8.359, *P*=.004), as shown in [Table 2](#T2){ref-type="table"}.

###### 

Demographic Characteristics of MDD Patients and Baseline HDRS-17 Scores between Responder and Nonresponder Groups

  Demographic Characteristics                 Responder (n = 205)   Nonresponder (n = 76)   F/ χ2   *P* Value
  ------------------------------------------- --------------------- ----------------------- ------- -----------
  Age (y)                                     38.99±12.93           36.18±13.36             2.556   0.111
  Gender, male (female)                       39.5% (60.5%)         46.1% (53.9%)           0.978   0.323
  Antidepressant, SSRI (SNRI)                 55.1% (44.9%)         65.8% (34.2%)           2.590   0.108
  Duration of illness (mo)                    48.42±75.63           49.78±68.83             0.019   0.892
  Family history of mood disorder, yes (no)   16.1% (83.9%)         23.7% (76.3%)           2.148   0.143
  First episode, yes (no)                     51.7% (48.3%)         46.1% (53.9%)           0.709   0.400
  Education, (y)                              11.28±3.71            12.20±3.71              3.400   0.066
  Baseline HDRS-17 score                      28.18±5.68            26.01±5.32              8.359   0.004

An analysis of single locus effects revealed that 2 SNPs, rs11178998 and rs7963717, in TPH2 had a statistically significant association with antidepressant response, as shown in [Table 3](#T3){ref-type="table"}. There was genotypic association for each of these with antidepressant response in the total group and in the SSRI subgroup, respectively, which withstood permutation testing. There was allelic association of one further TPH2 SNP (rs2171363) with antidepressant response in total group, withstanding permutation testing.

###### 

Genetic Association Analysis (Genotypic/Allelic) of SNPs vs Response Status in Total Group and the SSRI Subgroups

  Gene/rs\#                 Genotype/Allele   RES   NR      RES-freq(%)   NR-freq(%)   *P*      *P*\*\*                OR (95%CL)
  ------------------------- ----------------- ----- ------- ------------- ------------ -------- ---------------------- ----------------------
  Total group (n = 281)                                                                                                
  TPH2/rs11178998           AA                149   45      72.68         59.21        .03002   .03996                 1.833 (1.056--3.18)
  AA/AG\*                   56                31    27.32   40.79         .03002                                       
  TPH2/rs7963717            AA                150   46      73.17         60.53        .04039   .03297                 1.779 (1.022--3.096)
  AC+CC\*                   55                30    26.83   39.47         .04039                                       
  TPH2/ rs2171363           A\*               210   94      51.22         61.84                                        
  G                         200               58    48.78   38.16         .02478       .01598   1.544 (1.055--2.258)   
  SSRI subgroup (n = 164)                                                                                              
  TPH2/rs11178998           AA                81    26      71.05         52.00        .01834   .02098                 2.266 (1.14--4.503)
  AA/AG\*                   33                24    28.95   48.00                                                      
  TPH2/rs7963717            AA                82    27      71.93         54.00        .02516   .02398                 2.183 (1.095--4.352)
  AC+CC\*                   32                23    28.07   46.00                                                      

We examined the association of haplotypes derived from the SNPs in every gene with antidepressant response, limiting our analysis to haplotypes with a frequency ≥5%. Significant results were only found for TPH2. [Table 4](#T4){ref-type="table"} shows the 2 haplotypes of *TPH2* in relation to antidepressant response. The A-A haplotype was significantly associated with antidepressant response in the total group and in the SSRI subgroup, which withstood permutation testing. Compared with the A-G haplotype, the A-A haplotype was associated with increased likelihood of poor response in the total group (OR=0.6959, 95% CI=0.4259--1.136) and in the SSRI subgroup (OR=0.5526, 95% CI=0.2898--1.054). With the 3 SNPs of TPH2, the G-G-A haplotype was associated with antidepressant response in the total group (OR=1.986, 95% CI=1.018--3.872), but not withstanding permutation testing.

###### 

Estimated Haplotype Frequency of the TPH2 SNPs and the Results of Haplotype Analysis in Responders and Nonresponders

  Gene/rs\#                              Haplotype   RES     NR      RES-freq(%)   NR-freq(%)   *P*       *P*\*\*                OR (95%CL)
  -------------------------------------- ----------- ------- ------- ------------- ------------ --------- ---------------------- ------------------------
  Total group (n = 281)                                                                                                          
  TPH2/rs2171363, rs1487278              A-A         87.9    48      21.54         31.58        .01153    .03996                 0.6959 (0.4259--1.136)
  A-G\*                                  121.1       46      29.68   30.26                                                       
  G-A                                    195.1       58      47.82   38.16                                                       
  TPH2/rs1386494, rs2171363, rs1487278   A-A-A       28.85   17      70.70         11.18                                         
  G-A-A                                  58.71       31      14.39   20.39                                                       
  G-A-G\*                                120.3       46      29.48   30.26                                                       
  G-G-A                                  195.4       58      47.90   38.16         .0364        *.1239*   1.986 (1.018--3.872)   
  SSRI subgroup (n = 164)                                                                                                        
  TPH2/rs2171363, rs1487278              A-A         44.53   32      19.53         32.00        .01203    .02697                 0.5526 (0.2898--1.054)
  A-G\*                                  65.47       26      28.72   26.00                                                       
  G-A                                    115.5       42      50.65   42.00                                                       

Among 281 subjects, 208 completed the CTQ-SF, of whom 68 were categorized as high adversity based on their CTQ-SF score, and 219 completed the LES, of whom 78 were in the high adversity category based on their nLES score. In logistic regression analyses, there was no significant association between the categories derived from CTQ-SF or NLES and antidepressant outcome in the stepwise logistic regression model (results not shown). A further analysis searching for the interaction of these environmental measures with genotype in treatment response was then tested on the 3 SNPs with significant effects in the simple association analysis (rs11178998, rs7963717, rs2171363). A significant interaction between the TPH2 SNP rs2171363 and CTQ-SF category was identified in the effect on antidepressant response, adjusting for age, gender, and HDRS-17 baseline scores as covariates. The results are shown in [Table 5](#T5){ref-type="table"} (nonsignificant results not shown). In the regression model with CTQ-SF and rs2171363, the interaction term (CTQ-SF by rs2171363 GG genotype) was associated with reduced response to antidepressants, with the CTQ low adversity and rs2171363 AG/AA serving as reference (β=-2.432, SE=1.060, OR=0.088, 95%CI: 0.011--0.702). A further exploratory analysis searching for gene-environment interactions in the remaining SNPs identified no additional significant effects before any correction for multiple testing.

###### 

Results of the Interactions between rs2171363 and CTQ-SF on Antidepressant Response Adjusting for Age, Gender, and Baseline HDRS-17 Score

                                    β        SE      *P*     Odds Ratio   95% CI
  --------------------------------- -------- ------- ------- ------------ ---------------
  Baseline HDRS-17 score            0.112    0.033   0.001   1.118        1.049--1.192
  Gender                            0.222    0.336   0.509   1.248        0.646--2.411
  Age                               -0.005   0.013   0.713   0.995        0.969--1.021
  CTQ-SF                            0.205    0.376   0.585   1.227        0.588--2.564
  rs2171363                         2.019    0.776   0.009   7.529        1.646--34.434
  rs2171363 by CTQ-SF interaction   -2.432   1.060   0.022   0.088        0.011--0.702

Abbreviation: CTQ-SF, Childhood Trauma Questionnaire.

Discussion {#s8}
==========

In the initial investigation of associations of variants in monoamine neurotransmitter system gene with antidepressant response in patients with MDD, we found that SNPs in TPH2 were significantly associated with antidepressant response, and an interaction of one SNP in TPH2 and early life stress was also associated with antidepressant response.

There were genotypic associations for rs11178998, rs7963717, and rs2171363 in TPH2 with antidepressant response in the total group and, for the first two, in the SSRI subgroup. rs11178998 is located in the 5' UTR and has previously been reported to be associated with bipolar disorder ([@CIT0008]). Furthermore, rs11178998 and rs7963717 were found to be in very high linkage disequilibrium in our study ([Table 6](#T6){ref-type="table"}), indicating that the finding may be due to the functional effect of a single SNP. There is also high linkage disequilibrium (D'=1, r^2^\>0.99) between rs11178997 and rs11178998 reported in Chinese subjects, these SNPs also showing strong linkage with rs4570625 in the 5' region ([@CIT0038]).

###### 

Linkage Disequilibrium among SNPs in TPH2

  TPH2             rs7305115^*a*^   rs4290270^*a*^   rs7963717   rs4570625   rs11178998   rs7954758   rs1386494   rs2171363   rs1487278   rs1386483   rs1487279 (D')
  ---------------- ---------------- ---------------- ----------- ----------- ------------ ----------- ----------- ----------- ----------- ----------- ----------------
  rs7305115^*a*^                    0.69             0.41        0.70        0.41         0.39        1           0.98        0.94        0.71        0.66
  rs4290270^*a*^   0.48                              0.41        0.48        0.44         0.35        0.63        0.68        0.64        0.99        0.94
  rs7963717        0.02             0.02                         1           1            0.97        0.78        0.42        0.91        0.50        0.54
  rs4570625        0.46             0.22             0.15                    1            1           0.37        0.72        0.83        0.49        0.49
  rs11178998       0.02             0.03             0.97        0.15                     0.97        0.64        0.38        0.92        0.53        0.57
  rs7954758        0.02             0.02             0.92        0.14        0.89                     0.73        0.40        1           0.46        0.52
  rs1386494        0.07             0.03             0.01        0.01        0            0                       1           0.86        0.57        0.67
  rs2171363        0.95             0.46             0.02        0.49        0.02         0.02        0.07                    0.94        0.71        0.66
  rs1487278        0.32             0.14             0.06        0.24        0.07         0.08        0.03        0.33                    0.66        0.62
  rs1386483        0.48             0.95             0.03        0.24        0.04         0.03        0.02        0.47        0.15                    0.96
  rs1487279 (r2)   0.44             0.87             0.04        0.23        0.05         0.04        0.03        0.42        0.14        0.88        

D' and r^2^ value are shown above and below the diagonal, respectively.

^*a*^ SNPs of TPH2 mentioned in the previous research (Xu et al., 2012) with the same sample.

Results of a study investigating the effect of TPH2 promoter polymorphisms on transcriptional activity ([@CIT0029]) indicated that the A-allele of rs11178997 significantly reduces TPH2 transcriptional activity via an effect on transcription factor binding, while rs4570625 was found to have no influence on transcription. However, a subsequent study ([@CIT0007]) found both of these regulatory sequence SNPs influenced, in a synergistic manner, gene expression, while rs11178998 also had a strong effect on transcriptional activity independent of the other 2 SNPs. These data suggest that the functional effects of rs11178997 and/or rs11178998 may well contribute to the association of rs11178998 and rs7963717 with antidepressant response

Several other groups have shown association of rs4570625 with psychiatric disorders, including schizophrenia ([@CIT0039]) and epileptic psychosis ([@CIT0006]) and, interestingly in this context, an interaction of the SNP with maternal depression in infant response to fearful expression ([@CIT0013]). However, we find that this SNP is not significantly related to outcome measures in our study. This is likely due to the fact that while this SNP is in linkage disequilibrium with the functional rs11178997 and the closely linked rs11178998 that we measured, the MAFs are very different, resulting in r^2^=0.15.

The third TPH2 SNP, rs2171363, significantly associated with antidepressant response in the total group, but not with the SSRI subgroup, was also associated with antidepressant response in another study of Chinese patients ([@CIT0035]). This effect may be additional to that of the 2 promoter SNPs; rs2171363 is found in a large intronic sequence approximately 30kb removed from the 5' regulatory sequence and this SNP is not in strong linkage disequilibrium with the previous 2 ([Table 6](#T6){ref-type="table"}).

This rs2171363, but not the 2 other SNPs significantly associated with antidepressant response, shows a significant interaction with early life stress in this effect. This finding, in which the GG genotype and high childhood adversity were related to poor treatment response, is notable in light of our initial finding of such a gene-environment interaction with antidepressant response with this sample ([@CIT0041]). The current findings appear to be a replication of the original effect; rs2171363 and the previously reported rs7305115 are in close linkage disequilibrium and are thus likely to show any association together. The mechanism underlying the association with antidepressant response is unclear; rs2171363 is intronic, while rs7305115 is a synonymous exonic SNP. However, there is a report that these are 2 of 5 SNPs within a closely linked haplotype block, each correlating with TPH2 mRNA expression ([@CIT0022]).

Furthermore, the mechanism underlying the interactions between genetic variation in TPH2 and early stressors is also far from clear. One speculative explanation for the gene-environment interaction in our study might be that early life stress results in epigenetic changes such as DNA methylation and that this may interact with proximal polymorphisms, perhaps by influencing transcription factor binding, to modify gene expression. There is certainly evidence for this in terms of the relationship between early life stress and depression ([@CIT0009]) and has also been indicated as a factor influencing treatment response of some symptoms in schizophrenia ([@CIT0033]).

The 2 TPH2 SNPs that showed no significant effects in our genotype and allele analysis, rs1487278 and rs1386494, have previously been reported to be associated with antidepressant response and treatment resistant depression, respectively ([@CIT0036]; [@CIT0002]; [@CIT0035]). Haplotype analysis undertaken according to the haplotype blocks defined by the SNPs in this study has not shown any effect stronger than individual significant component SNPs.

The results of this study would benefit from being replicated in a further sample, and a second collection is currently underway to address this. It would also be valuable to know whether the findings could be extrapolated to other ethnicities. As with all such studies, a larger sample would be more informative; this could enable the investigation of possible differential effects of sex, individual drugs, and further social or epidemiological variables as well as permitting better study of gene interactions with these factors and between genes. Furthermore, the differences in significant association between the whole sample and the SSRI subgroup may reflect the limited sample size rather than any subgroup specificity. We recognize that the retrospective and subjective determination of prior stressors is imprecise, and treating these as dichotomized categorical variables limits the analytical power. It is important to recognize that in this small study we have not investigated all the genetic factors that might contribute to functional effects on serotonin or noradrenaline neurotransmission, nor have we comprehensively assessed the genetic variability within the chosen candidate genes, having selected specific SNPs on the basis of prior study and likely or known functionality. Nevertheless, our findings provide an interesting and potentially valuable insight into possible genetic factors and gene-environment interactions that influence outcome in the treatment of depression.

In conclusion, we find 3 associations of genetic variability within TPH2 with response to treatment in our sample of Chinese subjects with depression. Only one of these demonstrates an interaction with early life stress, a finding which suggests a sequence-specific epigenetic consequence of this environmental factor that may be modified by the identified polymorphism, or one in close linkage. Further study needs to identify the effects of these genetic variants on gene expression and on the possible mechanisms relating early life stress to response to treatment with antidepressant drugs.
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